Unknown PHASE1 INTERVENTIONAL 1-arm NCT05113069

A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1912 for Injection as Monotherapy in Patients With B-cell Lymphoma

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.

Conditions B Cell Lymphoma

Interventions SHR-A1912

Updated 8 times since 2021 Last updated: Nov 29, 2023 Started: Dec 22, 2021 Primary completion: Mar 31, 2024 Completion: Mar 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on B Cell Lymphoma, this trial is ongoing. The trial is conducted by Shanghai Hengrui Pharmaceutical Co., Ltd. and has accumulated 8 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1

Status: Enrolling By Invitation → Unknown
Sep 2024 — Jan 2026 [monthly]

Enrolling By Invitation PHASE1
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE1
Jan 2024 — Jul 2024 [monthly]

Enrolling By Invitation PHASE1

Status: Recruiting → Enrolling By Invitation
Jul 2023 — Jan 2024 [monthly]

Recruiting PHASE1

▶ Show 3 earlier versions

May 2022 — Jul 2023 [monthly]

Recruiting PHASE1
Jan 2022 — May 2022 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Dec 2021 — Jan 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Hengrui Pharmaceutical Co., Ltd.

Data source: Shanghai Hengrui Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China